How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?
Kura K, Stolk W, Basáñez M, Collyer B, de Vlas S, Diggle P, Gass K, Graham M, Hollingsworth T, King J, Krentel A, Anderson R, Coffeng L. How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis? Clinical Infectious Diseases 2024, 78: s93-s100. PMID: 38662701, PMCID: PMC11045024, DOI: 10.1093/cid/ciae021.Peer-Reviewed Original ResearchConceptsMass drug administrationElimination of lymphatic filariasisEfficacious treatment regimensLymphatic filariasisLevels of NTMass drug administration programmesYears of annual treatmentTreatment regimensDrug combinationsTransmission settingsMass drug administration programsDrug AdministrationTreatment coveragePrevalenceTransmission areasMDA coverageBaselineProportion of peopleTreatmentPrevalence thresholdImpact of NTAlbendazoleDiethylcarbamazineHighest infection prevalenceHighest proportionA Comparison of Markov and Mechanistic Models for Soil-Transmitted Helminth Prevalence Projections in the Context of Survey Design
Eyre M, Bulstra C, Johnson O, de Vlas S, Diggle P, Fronterrè C, Coffeng L. A Comparison of Markov and Mechanistic Models for Soil-Transmitted Helminth Prevalence Projections in the Context of Survey Design. Clinical Infectious Diseases 2024, 78: s146-s152. PMID: 38662703, PMCID: PMC11045013, DOI: 10.1093/cid/ciae022.Peer-Reviewed Original ResearchConceptsOptimal survey designImpact assessment surveysSurvey designProjected prevalenceGeostatistical methodsPrevalence surveySampling designSchool-aged childrenPreventive chemotherapySoil-transmitted helminthsPrevalence projectionsControl programsWorld Health OrganizationAssessment surveyPrevalence dataSub-Saharan AfricaMechanistic modelTarget of PCSoutheast AsiaHealth OrganizationMechanistic methodsPrevalenceBillion peopleSub-SaharanInadequate sanitationImproving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis
Coffeng L, Graham M, Browning R, Kura K, Diggle P, Denwood M, Medley G, Anderson R, de Vlas S. Improving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis. Clinical Infectious Diseases 2024, 78: s153-s159. PMID: 38662699, PMCID: PMC11045014, DOI: 10.1093/cid/ciae020.Peer-Reviewed Original Research